Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.8
Journals
Healthcare
Special Issues
Research Advances in Liver Disease
share announcement

Research Advances in Liver Disease

A special issue of Healthcare (ISSN 2227-9032).

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2085

Special Issue Editors

Prof. Dr. Rena Fox

E-Mail Website
Guest Editor
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
Interests: hepatitis C virus; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; cirrhosis; hepatocellular carcinoma; screening; primary care; chronic liver disease
Dr. Jennifer C. Price

E-Mail Website
Guest Editor
Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA, USA
Interests: hepatitis C virus; hepatitis B virus; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; cirrhosis; hepatocellular carcinoma; alcoholic liver disease; chronic liver disease

Special Issue Information

Dear Colleagues,

This Special Issue will facilitate the publication of high-quality manuscripts covering important current topics in clinical liver disease management. In particular, the Issue will highlight work harnessing community partnerships, leveraging informatics, and mobilizing healthcare systems to address disparities in chronic liver disease and challenges in real-world clinical practice.

The goal of this Special Issue is to provide a platform for researchers, clinicians, policy makers, and community leaders around the globe to share innovations, therapies and new approaches in hepatology. We welcome original full-length articles, reviews, and editorials on epidemiology, prevention, diagnostics, treatment and management of patients with liver disease.

Prof. Dr. Rena Fox
Dr. Jennifer C. Price
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis C virus
  • hepatitis B virus
  • cirrhosis
  • alcoholic liver disease
  • hepatocellular
  • carcinoma
  • nonalcoholic fatty liver disease
  • metabolic fatty liver disease
  • fatty liver disease
  • steatosis
  • screening
  • biomarkers
  • FIB-4
  • informatics
  • epidemiology
  • direct acting antivirals
  • obesity
  • community partnerships
  • disparities

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

16 pages, 1412 KiB  
Review
Care for Vulnerable Populations with Chronic Liver Disease: A Safety-Net Perspective
by Mark C. Wang, Saroja Bangaru and Kali Zhou
Healthcare 2023, 11(20), 2725; https://doi.org/10.3390/healthcare11202725 - 13 Oct 2023
Viewed by 1077
Abstract
Safety-net hospitals (SNHs) and facilities are the cornerstone of healthcare services for the medically underserved. The burden of chronic liver disease—including end-stage manifestations of cirrhosis and liver cancer—is high and rising among populations living in poverty who primarily seek and receive care in [...] Read more.
Safety-net hospitals (SNHs) and facilities are the cornerstone of healthcare services for the medically underserved. The burden of chronic liver disease—including end-stage manifestations of cirrhosis and liver cancer—is high and rising among populations living in poverty who primarily seek and receive care in safety-net settings. For many reasons related to social determinants of health, these individuals often present with delayed diagnoses and disease presentations, resulting in higher liver-related mortality. With recent state-based policy changes such as Medicaid expansion that impact access to insurance and critical health services, an overview of the body of literature on SNH care for chronic liver disease is timely and informative for the liver disease community. In this narrative review, we discuss controversies in the definition of a SNH and summarize the known disparities in the cascade of the care and management of common liver-related conditions: (1) steatotic liver disease, (2) liver cancer, (3) chronic viral hepatitis, and (4) cirrhosis and liver transplantation. In addition, we review the specific impact of Medicaid expansion on safety-net systems and liver disease outcomes and highlight effective provider- and system-level interventions. Lastly, we address remaining gaps and challenges to optimizing care for vulnerable populations with chronic liver disease in safety-net settings. Full article
(This article belongs to the Special Issue Research Advances in Liver Disease)
►▼ Show Figures

Figure 1

Other

Jump to: Review

9 pages, 1207 KiB  
Study Protocol
Staff-Facilitated Telemedicine Care Delivery for Treatment of Hepatitis C Infection among People Who Inject Drugs
by Rebecca G. Kim, Claire McDonell, Jeff McKinney, Lisa Catalli, Jennifer C. Price and Meghan D. Morris
Healthcare 2024, 12(7), 715; https://doi.org/10.3390/healthcare12070715 - 25 Mar 2024
Viewed by 643
Abstract
Background: Telemedicine offers the opportunity to provide clinical services remotely, thereby bridging geographic distances for people engaged in the medical system. Following the COVID-19 pandemic, the widespread adoption of telemedicine in clinical practices has persisted, highlighting its continued relevance for post-pandemic healthcare. Little [...] Read more.
Background: Telemedicine offers the opportunity to provide clinical services remotely, thereby bridging geographic distances for people engaged in the medical system. Following the COVID-19 pandemic, the widespread adoption of telemedicine in clinical practices has persisted, highlighting its continued relevance for post-pandemic healthcare. Little is known about telemedicine use among people from socially marginalized groups. Methods: The No One Waits (NOW) Study is a single-arm clinical trial measuring the acceptability, feasibility, and safety of an urban point-of-diagnosis hepatitis C (HCV) treatment initiation model delivered in a non-clinical community setting. Participants enrolled in the NOW Study are recruited via street outreach targeting people experiencing homelessness and injecting drugs. Throughout the NOW Study, clinical care is delivered through a novel staff-facilitated telemedicine model that not only addresses geographic and transportation barriers, but also technology and medical mistrust, barriers often unique to this population. While clinicians provide high-quality specialty practice-based care via telemedicine, on-site staff provide technical support, aid in communication and rapport, and review the clinicians’ instructions and next steps with participants following the visits. Research questionnaires collect information on participants’ experience with and perceptions of telemedicine (a) prior to treatment initiation and (b) at treatment completion. Discussion: For people from socially marginalized groups with HCV infection, creative person-centered care approaches are necessary to diagnose, treat, and cure HCV. Although non-clinical, community-based staff-facilitated telemedicine requires additional resources compared to standard-of-care telemedicine, it could expand the reach and offer a valuable entrance into technology-delivered care for socially marginalized groups. Trial registration: NCT03987503. Full article
(This article belongs to the Special Issue Research Advances in Liver Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop